Last updated: 11/07/2018 18:46:46
A phase IIIB, multi-centre, double-blind, parallel group, randomised study to compare the efficacy of the salmeterol/fluticasone propionate combination (25/50 mcg strength), 2 inhalations bd via HFA-MDI with beclomethasone dipropionate (BDP) 200mcg bd via metered...
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A phase IIIB, multi-centre, double-blind, parallel group, randomised study to compare the efficacy of the salmeterol/fluticasone propionate combination (25/50 mcg strength), 2 inhalations bd via HFA-MDI with beclomethasone dipropionate (BDP) 200mcg bd via metered...
Trial description: A phase IIIB, multi-centre, double-blind, parallel group, randomised study to compare the efficacy of the salmeterol/fluticasone propionate combination (25/50 mcg strength), 2 inhalations bd via HFA-MDI with beclomethasone dipropionate (BDP) 200mcg bd via metered...
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: A comparison of the efficacy of salmeterol/fluticasone propionate combination (sf) with beclometasone dipropionate (bdp) delivered via metered dose inhaler (mdi) in patients not well controlled on bronchodilators alone. McCarthy, T. P., Russell, D., Baxter, L. E., Shrewsbury, S. B., and Rice, L. 11th Annual Congress of the European Respiratory Society 9/22/2001 Berlin; Germany
Abstract: Asthma costs with salmeterol/fluticasone combination 50/250mcg bd compared to budesonide 800mcg bd plus formoterol 12meg bd. A.A. Martin, P. J. Whitehead T. P. McCarthy. 99th International Conference of the American Thoracic Society 5/16/2003 Seattle WA
Abstract: Improved compliance with asthma therapy in children treated with salmeterol/fluticasone propionate combination (sfc) compared with concurrent salmeterol (s) plus inhaled corticosteroid (ics) or ics alone. T.P. McCarthy, L. Rice C. A. Blair. 99th International Conference of thAmerican Thoracic Society 5/16/2003
Abstract: Salmeterol/fluticasone propionate combination (sfc) demonstrates improved health outcomes and good cost effectiveness compared with beclometasone dipropionate. Tolley, K, Martin, A, Rice, L, and McCarthy, T P 98th International Conference of the American Thoracic Society 5/17/2002 Atlanta, GA
Abstract: Salmeterol/fluticasone propionate combination is more effective than beclomethasone dipropionate in patients not well controlled on bronchodilators alone. McCarthy, T P, Greening, A P, Holgate, S K, Whitehead, C, and Rice, L 98th International Conference of the American Thoracic Society 5/17/2002 Atlanta, GA
Abstract: The efficacy of salmeterol/fluticasone propionate combination (sfc) metered dose inhaler compared with beclometasone dipropionate (bdp) in patients not well controlled at step 1 of the british guidelines on asthma management (bgam). McCarthy, T P, Whitehead, C, Rice, L, Greening, A P, and Holgate, S K Winter Meeting of the British Thoracic Society 12/5/2001 London UK
Angus R, Reagon R, Cheesbrough A. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. International Journal of Clinical Practice 2005; 59(2):156-62.
McCarthy TP, Greening AP, Holgate SK, Whitehead C, Rice L. Salmeterol/fluticasone propionate combination (SFC) is more effective than beclometasone dipropionate (BDP) in patients not well controlled on bronchodilators alone. Am J Respir Crit Care Med 2002; 165 (8): A566
McCarthy TP, Greening AP, Holgate SK, Whitehead C, Rice L. The efficacy of salmeterol/fluticasone propionate combination (SFC) metered dose inhaler compared with beclometasone dipropionate (BDP) in patients not well controlled at step 1 f the British Guidelines on Asthma Management (BGAM). Thorax 2001; 56 (Suppl III): 62
McCarthy TP, Russell D, Baxter LE et al. A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone. Eur Respir J 2001; 18 (Suppl 33): 53-54s
Tolley K, Martin A, Rice L, McCarthy TP. Salmeterol/fluticasone propionate combination (SFC) demonstrates improved health outcomes and good cost-effectiveness compared with beclometasone dipropionate. Am J Respir Crit Care Med 2002; 165 (8): A112
Medical condition
Asthma
Product
fluticasone propionate/salmeterol
Collaborators
Not applicable
Study date(s)
January 2000 to November 2000
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2000-03-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website